title: [Kinetic and organization of granulocytes transfusion: a case report].
abstract: BACKGROUND
  Therapeutic granulocyte transfusion remains an indication for neutropenic sepsis associated with prolonged neutropenia. However, harvest complexity and lack of proved efficacy mark the limits of its development.
  
  
  METHODS
  A 58-year old man received allogeneic stem cell transplantation for osteomyelofibrosis. Six months later, after a transplant rejection, he presented with perineal cellulitis from hemorrhoid origin, without any microbiological documentation. The evolution was unfavorable despite antibiotic and antifungal therapy. A set of seven granulocytes transfusions was initiated. Re-circulation of granulocytes analysis showed an initial increase (H2) followed by a decrease (H8) reaching the basal rate at H16. No toxicity has been reported during or following the transfusions. Clinical improvement has been reported five days after the first transfusion, scaring over at D15, without any neutrophil recovery.
  
  
  CONCLUSIONS
  In 2014, granulocyte transfusion therapy is indicated for severe infection associated with long-term neutropenia. Minimal circulation of transfused cells in our observation and fast clinical improvement suggest the concentration of granulocytes on the infected area.
authors.affiliation: Équipe hématologie clinique, département d'hématologie clinique, CHRU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex, France.
authors.forename: S
authors.initials: S
authors.lastname: Lamure
authors.affiliation: Équipe hémovigilance et aphérèse thérapeutique, département d'hématologie clinique, CHRU de Montpellier, 34295 Montpellier cedex, France.
authors.forename: P
authors.initials: P
authors.lastname: Latry
authors.affiliation: Équipe hémovigilance et aphérèse thérapeutique, département d'hématologie clinique, CHRU de Montpellier, 34295 Montpellier cedex, France.
authors.forename: T
authors.initials: T
authors.lastname: Kanouni
authors.affiliation: Équipe hématologie clinique, département d'hématologie clinique, CHRU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Hicheri
authors.affiliation: Équipe hématologie clinique, département d'hématologie clinique, CHRU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex, France.
authors.forename: A
authors.initials: A
authors.lastname: Sirvent
authors.affiliation: Équipe hématologie clinique, département d'hématologie clinique, CHRU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex, France.
authors.forename: A
authors.initials: A
authors.lastname: Lenglet
authors.affiliation: Établissement français du sang Pyrénées-Méditerranée, 34184 Montpellier, France.
authors.forename: D
authors.initials: D
authors.lastname: Mathieu-Daude
authors.affiliation: Établissement français du sang Pyrénées-Méditerranée, 34184 Montpellier, France.
authors.forename: P
authors.initials: P
authors.lastname: Cazal
authors.affiliation: Équipe hématologie clinique, département d'hématologie clinique, CHRU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex, France. Electronic address: g-cartron@chu-montpellier.fr.
authors.forename: G
authors.initials: G
authors.lastname: Cartron
mesh_terms: D064591:Allografts; D000890:Anti-Infective Agents / Q000627:therapeutic use; D002481:Cellulitis / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D003131:Combined Modality Therapy; D006084:Graft Rejection / Q000188:drug therapy; D006098:Granulocytes / Q000637:transplantation*; D018380:Hematopoietic Stem Cell Transplantation; D006484:Hemorrhoids / Q000150:complications; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D017708:Leukocyte Transfusion; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000209:etiology / Q000628:therapy*; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000628:therapy; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines; D012772:Shock, Septic / Q000209:etiology; D013156:Splenectomy / Q000009:adverse effects
chemical_list: D000890:Anti-Infective Agents; D007166:Immunosuppressive Agents; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib
keywords: Granulocytes transfusion; Osteomyelofibrosis; Ostéomyélofibrose; Transfusion granulocytes